The UK may regret missed opportunities to retain its researchers if the closure of the Novartis site in West Sussex goes ahead, the Royal Society of Chemistry has said.
Novartis announced on 7 November that it was consulting on whether to close the site in Horsham, putting 371 jobs at risk. In an email to Research Fortnight on the same day, the company said that 306 of those jobs were in research and 45 in development.
Robert Parker, chief executive of the RSC, said in a statement that he was worried about the closure of pharmaceutical companies in the UK, with “this latest development following closures at AstraZeneca in spring this year and at Pfizer three years ago”.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.